Table 5.
Cox regression analyses of PD1 and PDL1 gene expression levels in early and late stage squamous cell carcinoma lung cancer patients.
| Early stage | ||||||
|---|---|---|---|---|---|---|
| Outcomes | HR (95% CI) b | P-value | ||||
| Alive | Dead | |||||
| Number (%) | Number (%) | P-value a | ||||
| Univariate | ||||||
| PD1 <= 6.98 | 55 (50.46) | 54 (49.54) | 0.1791 | Ref. | ||
| PD1 > 6.98 | 47 (61.04) | 30 (38.96) | 0.72 (0.46 ~ 1.13) | 0.1552 | ||
| PDL1 <= 7.03 | 30 (43.48) | 39 (56.52) | 0.0220 | Ref. | ||
| PDL1 > 7.03 | 72 (61.54) | 45 (38.46) | 0.68 (0.44 ~ 1.04) | 0.0773 | ||
| Additive model c | 0.72 (0.53 ~ 0.97) | 0.0300 | ||||
| Number of higher expression PD1/PDL1 | 0.0175 | |||||
| 0 higher expression gene | 17 (36.96) | 29 (63.04) | Ref. | |||
| 1 higher expression gene | 51 (59.30) | 35 (40.70) | 0.57 (0.35 ~ 0.94) | 0.0267 | ||
| 2 higher expression gene | 34 (62.96) | 20 (37.04) | 0.54 (0.31 ~ 0.96) | 0.0347 | ||
| Late stage | ||||||
| Outcomes | ||||||
| Alive | Dead | |||||
| Number (%) | Number (%) | P-value a | HR (95% CI) b | P-value | ||
| Univariate | ||||||
| PD1 <= 6.88 | 58 (45.31) | 70 (54.69) | 0.0929 | Ref. | ||
| PD1 > 6.88 | 59 (35.12) | 109 (64.88) | 1.12 (0.83 ~ 1.52) | 0.4569 | ||
| PDL1 <= 7.39 | 59 (45.74) | 70 (54.26) | 0.0566 | Ref. | ||
| PDL1 > 7.39 | 58 (34.73) | 45 (65.27) | 1.33 (0.99 ~ 1.80) | 0.0621 | ||
| Additive model c | 1.21 (0.98 ~ 1.48) | 0.0747 | ||||
| Number of higher expression PD1/PDL1 | 0.0461 | |||||
| 0 higher expression gene | 32 (49.23) | 33 (50.77) | Ref. | |||
| 1 higher expression gene | 53 (41.73) | 74 (58.27) | 1.02 (0.68 ~ 1.54) | 0.9222 | ||
| 2 higher expression gene | 32 (30.77) | 72 (69.23) | 1.38 (0.92 ~ 2.09) | 0.1242 | ||
HR: Hazard ratio, CI: confidence interval, Ref.: reference group
a
P-value for Fisher exact test.
b
Adjusted for age and gender.
c
Trend test for additive model.
Bold face: statistically significant (P value<0.05).